We recently published a list of 12 Best Performing Cheap Stocks in 2024. In this article, we are going to take a look at where Sensus Healthcare, Inc. (NASDAQ:SRTS) stands against other best performing cheap stocks in 2024.
As we step into the final quarter of 2024, the financial markets continue to navigate a complex terrain shaped by a mix of optimism and uncertainty. The latest jobs report for September came in stronger than expected, signaling resilience in the U.S. labor market and leading many investors to reassess their expectations regarding the Federal Reserve’s monetary policy. This report has led traders to largely eliminate the possibility of a more significant rate cut, now forecasting an 87% chance of a quarter-point reduction in the near future. Despite these concerns, analysts are generally optimistic about the broader market’s prospects as we head towards year-end, thanks to promising earnings growth and stabilizing economic indicators.
Goldman Sachs, one of the leading voices on Wall Street, recently revised its target for a major stock market index upward, projecting that the index will reach 6,000 by the end of 2024. This forecast implies a 4.3% upside from current levels and reflects the bank’s confidence in sustained earnings growth throughout the remainder of the year. The bank also sees a longer-term target of 6,300 for the index, which would represent a 9.5% gain over the next 12 months. Chief U.S. equity strategist David Kostin noted that despite near-term volatility, factors like a recovery in the semiconductor cycle and easing cost pressures are likely to boost margins across multiple sectors. Such bullish sentiment suggests that investors looking for value opportunities might find them in underperforming but fundamentally sound sectors.
One area that stands out in terms of valuations and future potential is the biopharmaceutical industry. Experts like Karen Firestone, a seasoned investor and regular contributor to CNBC, highlight that despite the sector’s recent struggles, it presents an attractive entry point for long-term investors. Large pharmaceutical companies are trading at lower price-to-earnings ratios compared to the broader market, offering robust profit margins and potential for AI-driven breakthroughs in drug development. While some big names have rallied on the back of their blockbuster obesity drugs, the broader biopharma sector remains relatively undervalued.
This favorable setup is not confined to biopharma alone. The technology and consumer discretionary sectors, which were hit hard earlier this year, are also starting to show signs of life. According to FactSet, analysts expect the major stock index to post its fifth consecutive quarter of earnings growth in the third quarter, projecting a 4.2% expansion year-over-year. This suggests that sectors with solid growth fundamentals could outperform as economic conditions stabilize. At the same time, energy stocks, particularly those within the communication services sector, have received a higher percentage of “buy” ratings, reflecting optimism around their capacity to deliver gains in the coming months.
While there’s a lot of chatter around high-growth sectors, value investors are eyeing cheap stocks that have managed to deliver impressive returns. The biopharmaceutical sector is a case in point, where low valuations, high margins, and the potential integration of AI into drug discovery make it a compelling area for investment. Analysts suggest that companies with robust balance sheets and pricing power are best positioned to withstand potential economic headwinds and capitalize on emerging growth opportunities.
In addition, some strategists believe that broader market gains could extend beyond 2024, particularly if the Federal Reserve manages to engineer a “soft landing” by controlling inflation without triggering a recession. With the presidential election looming in 2025, historical data shows that major stock indices tend to perform well during election years, further supporting a cautiously optimistic outlook for equities.
Given these dynamics, it’s evident that while the market landscape is marked by volatility and economic uncertainties, there are still promising opportunities to be found. In the following sections, we delve into 12 of the best-performing cheap stocks of 2024, which have outpaced broader market indices and offer attractive entry points for investors looking to navigate these uncertain times with a focus on long-term gains.
Our Methodology
For this article, we used Finviz stock screener to look for companies having forward Price to Earnings (P/E) ratio of less than 15. We then selected the top 12 stocks with the best year-to-date performance. Additionally, we reviewed data from approximately 912 elite hedge funds tracked by Insider Monkey during the second quarter of 2024 to determine hedge fund ownership for each company. The stocks are ranked in ascending order of their year-to-date performance.
At Insider Monkey we are obsessed with the stocks that hedge funds pile into. The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points (see more details here).
A medical technician in a lab coat overseeing a radiation therapy device.
Sensus Healthcare, Inc. (NASDAQ:SRTS)
Number of Hedge Fund Holders: 7
Year to date Share Price Gain: 166.53%
Forward Price to Earnings (P/E) Ratio: 11.04
Sensus Healthcare, Inc. (NASDAQ:SRTS) is a medical device company that designs and sells advanced radiation therapy devices to healthcare providers across the globe. The company’s core technology, superficial radiation therapy (SRT), offers a non-invasive alternative to surgery for treating non-melanoma skin cancers, such as basal cell and squamous cell carcinomas, as well as other skin conditions like keloids. The company has a diversified product lineup, including the SRT-100 and SRT-100 Vision systems, both of which provide an effective, patient-friendly option for dermatology practices and hospital settings. Given its innovative offerings, strong revenue growth, and expanding market presence, Sensus Healthcare, Inc. (NASDAQ:SRTS) is a solid inclusion in our list of the 12 best performing cheap stocks in 2024.
In its Q2 2024 earnings call, Sensus Healthcare, Inc. (NASDAQ:SRTS) reported impressive financial performance, showcasing a substantial year-over-year revenue growth of 104% to $9.2 million, compared to $4.5 million in Q2 2023. This growth was driven by a notable increase in the number of SRT units shipped, from 13 units in Q2 2023 to 23 units in Q2 2024, including three systems delivered to international markets. The rise in shipments of the SRT-100 Vision systems, which feature image-guided technology, highlights the company’s ability to innovate and cater to the evolving needs of healthcare providers. Gross profit for the second quarter stood at $5.4 million, representing a margin of 58.7%, up from 57.9% in the previous year.
The introduction of the Fair Deal Agreement, a recurring revenue model launched in March, has been well-received, with 15 contracts already signed and expectations for the total to reach 50 by year-end. This initiative is expected to significantly contribute to recurring revenues starting in 2025. Additionally, Sensus Healthcare, Inc. (NASDAQ:SRTS) recent entry into new international markets, including its first-ever sale of the image-guided SRT-100 Vision system in Asia, signals strong potential for further expansion and revenue diversification.
The company’s robust balance sheet, with $19 million in cash and no outstanding debt, positions it well for continued growth. With increasing demand for non-invasive treatments and a growing customer base, Sensus Healthcare, Inc. (NASDAQ:SRTS) outlook remains positive, making it a compelling option for investors looking for high-growth potential at a reasonable valuation.
Overall, MU ranks 7th on our list of best performing cheap stocks in 2024. While we acknowledge the potential of MU as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than MU but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
READ NEXT: $30 Trillion Opportunity: 15 Best Humanoid Robot Stocks to Buy According to Morgan Stanley and Jim Cramer Says NVIDIA ‘Has Become A Wasteland’.
Disclosure: None. This article is originally published at Insider Monkey.